E. Widerlöv

2.6k total citations
46 papers, 2.2k citations indexed

About

E. Widerlöv is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, E. Widerlöv has authored 46 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cellular and Molecular Neuroscience, 16 papers in Molecular Biology and 8 papers in Psychiatry and Mental health. Recurrent topics in E. Widerlöv's work include Neuropeptides and Animal Physiology (15 papers), Receptor Mechanisms and Signaling (13 papers) and Stress Responses and Cortisol (7 papers). E. Widerlöv is often cited by papers focused on Neuropeptides and Animal Physiology (15 papers), Receptor Mechanisms and Signaling (13 papers) and Stress Responses and Cortisol (7 papers). E. Widerlöv collaborates with scholars based in Sweden, United States and Hungary. E. Widerlöv's co-authors include Markus Heilig, L. Lindström, Rolf Ekman, A.J. Prange, Peter W. Kalivas, D. A. Stanley, George R. Breese, Charles B. Nemeroff, László Vécsei and Claes Wahlestedt and has published in prestigious journals such as American Journal of Psychiatry, Stroke and Biological Psychiatry.

In The Last Decade

E. Widerlöv

44 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Widerlöv Sweden 22 1.5k 1.1k 282 255 238 46 2.2k
R. Steinberg France 27 1.9k 1.2× 1.6k 1.4× 311 1.1× 197 0.8× 129 0.5× 59 2.8k
R. Quirion Canada 24 1.4k 0.9× 1.1k 1.0× 195 0.7× 337 1.3× 103 0.4× 48 2.4k
Carina Stenfors Sweden 27 1.1k 0.7× 658 0.6× 305 1.1× 128 0.5× 208 0.9× 66 1.8k
Scott Minick United States 10 1.2k 0.8× 810 0.7× 555 2.0× 272 1.1× 79 0.3× 11 2.0k
Hemmie H.G. Berendsen Netherlands 23 732 0.5× 379 0.3× 179 0.6× 129 0.5× 582 2.4× 36 1.8k
F.B. Jolicoeur Canada 25 1.4k 0.9× 949 0.9× 97 0.3× 310 1.2× 98 0.4× 86 1.8k
William T. Chance United States 28 934 0.6× 571 0.5× 248 0.9× 495 1.9× 109 0.5× 78 2.0k
David G. Grahame‐Smith United Kingdom 23 1.3k 0.8× 779 0.7× 114 0.4× 74 0.3× 279 1.2× 40 2.1k
T. C. Westfall United States 24 1.4k 0.9× 1.3k 1.2× 119 0.4× 239 0.9× 74 0.3× 58 2.2k
P. Slater United Kingdom 30 2.2k 1.4× 1.2k 1.1× 107 0.4× 138 0.5× 412 1.7× 134 3.1k

Countries citing papers authored by E. Widerlöv

Since Specialization
Citations

This map shows the geographic impact of E. Widerlöv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Widerlöv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Widerlöv more than expected).

Fields of papers citing papers by E. Widerlöv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Widerlöv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Widerlöv. The network helps show where E. Widerlöv may publish in the future.

Co-authorship network of co-authors of E. Widerlöv

This figure shows the co-authorship network connecting the top 25 collaborators of E. Widerlöv. A scholar is included among the top collaborators of E. Widerlöv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Widerlöv. E. Widerlöv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Widerlöv, E., et al.. (1990). Pharmacokinetics of remoxipride in elderly psychotic patients. Acta Psychiatrica Scandinavica. 82(S358). 176–180. 11 indexed citations
4.
Vécsei, László, et al.. (1990). Somatostatin28(15–28), but not somatostatin28(1–12), affects central monoaminergic neurotransmission in rats. Neuropeptides. 16(4). 181–186. 11 indexed citations
5.
Heilig, Markus & E. Widerlöv. (1990). Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatrica Scandinavica. 82(2). 95–114. 157 indexed citations
6.
Widerlöv, E., et al.. (1989). Elevated CSF somatostatin concentrations in demented patients parallel improved psychomotor functions induced by integrity‐promoting care. Acta Psychiatrica Scandinavica. 79(1). 41–47. 37 indexed citations
7.
Lesch, Klaus‐Peter, E. Widerlöv, Rolf Ekman, et al.. (1989). The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls. Journal of Neural Transmission. 75(2). 111–118. 7 indexed citations
8.
Widerlöv, E., et al.. (1989). Arginine vasopressin, but not corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment. Journal of Neural Transmission. 75(2). 101–109. 26 indexed citations
9.
Bjartell, Anders, et al.. (1989). Reduction of immunoreactive ACTH in plasma following intra venous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 14(5). 347–355. 15 indexed citations
10.
Vécsei, László, et al.. (1989). Cysteamine and pantethine effects on passive avoidance behavior, shuttle box learning, open-field activity, striatal catecholamines and somatostatin.. PubMed. 299. 14–27. 6 indexed citations
11.
Widerlöv, E., L. Lindström, Claes Wahlestedt, & Rolf Ekman. (1988). Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. Journal of Psychiatric Research. 22(1). 69–79. 212 indexed citations
12.
Vécsei, László & E. Widerlöv. (1988). Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness An overview. Acta Psychiatrica Scandinavica. 78(6). 657–667. 27 indexed citations
13.
Kilts, Clinton D., David L Knight, Richard B. Mailman, E. Widerlöv, & George R. Breese. (1984). Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine.. Journal of Pharmacology and Experimental Therapeutics. 231(2). 334–342. 35 indexed citations
14.
Nemeroff, Charles B., Paul J. Manberg, & E. Widerlöv. (1983). Neuropeptides in cerebrospinal fluid and postmorten brain tissue of schizophrenics, Huntington's choreics, and normal controls. 19(3). 369–374. 3 indexed citations
15.
Ljungström, K G, H. Renck, Kjell Strandberg, et al.. (1983). Adverse reactions to dextran in Sweden 1970-1979.. PubMed. 149(3). 253–62. 44 indexed citations
16.
Lewis, Mark H., E. Widerlöv, David L Knight, Clinton D. Kilts, & Richard B. Mailman. (1983). N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function.. Journal of Pharmacology and Experimental Therapeutics. 225(3). 539–545. 24 indexed citations
17.
Widerlöv, E.. (1979). [Phenylpropanolamine-induced psychoses].. PubMed. 76(49). 4529–30. 2 indexed citations
18.
Lindström, Leena, et al.. (1978). [Current research on the endorphins in psychoses].. PubMed. 75(34). 2865–7. 1 indexed citations
19.
Terenius, Lars, Agneta Wahlström, L. Lindström, & E. Widerlöv. (1976). Increased CSF levels of endorphines in chronic psychosis. Neuroscience Letters. 3(3). 157–162. 168 indexed citations
20.
Widerlöv, E., et al.. (1975). Effect of intravenous atropine and methylatropine on heart rate and secretion of saliva in man. European Journal of Clinical Pharmacology. 8(3-4). 233–240. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Steinberg Breakdown of academic impact, for papers by R. Quirion Breakdown of academic impact, for papers by Carina Stenfors Breakdown of academic impact, for papers by Scott Minick Breakdown of academic impact, for papers by Hemmie H.G. Berendsen Breakdown of academic impact, for papers by F.B. Jolicoeur Breakdown of academic impact, for papers by William T. Chance Breakdown of academic impact, for papers by David G. Grahame‐Smith Breakdown of academic impact, for papers by T. C. Westfall Breakdown of academic impact, for papers by P. Slater
Rankless by CCL
2026